Repare Therapeutics (RPTX) said late Thursday it is refocusing its resources on advancing phase 1 clinical programs for RP-1664 in solid tumors and RP-3467 in certain types of cancer.
The company also intends to seek partnerships for lunresertib and camonsertib before starting the next trials.
The strategic realignment, combined with cost and headcount reductions, is expected to extend the company's funds of $153 million until mid-2027, it added.
Repare said it will discontinue other lunresertib and camonsertib studies unless a suitable development partner is found.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。